trending Market Intelligence /marketintelligence/en/news-insights/trending/BAXQFVP5gonjr67cahzncg2 content esgSubNav
In This List

US FDA approves Glenmark's generic hypertension drug

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


US FDA approves Glenmark's generic hypertension drug

Glenmark Pharmaceuticals Ltd. secured the U.S. Food and Drug Administration approval to market a generic version of Benicar.

Benicar is Daiichi Sankyo Co. Ltd.'s hypertension drug, and Glenmark will manufacture it at its facility in Goa, India.

Benicar generated $950 million in sales during the 12 months ending March, according to IMS Health data.